Kintara Therapeutics, Inc.
KTRA
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.52% | -15.69% | -26.74% | -24.88% | -26.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -42.88% | -44.31% | -43.93% | -38.61% | -34.77% |
| Operating Income | 42.88% | 44.31% | 43.93% | 38.61% | 34.77% |
| Income Before Tax | 43.20% | 44.33% | 43.86% | 38.87% | 35.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 43.20% | 44.33% | 43.86% | 38.87% | 35.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.20% | 44.33% | 43.86% | 38.87% | 35.36% |
| EBIT | 42.88% | 44.31% | 43.93% | 38.61% | 34.77% |
| EBITDA | 43.02% | 44.42% | 44.07% | 38.71% | 34.86% |
| EPS Basic | 77.15% | 65.31% | 60.85% | 59.22% | 66.58% |
| Normalized Basic EPS | 77.64% | 65.45% | 60.89% | 59.23% | 62.70% |
| EPS Diluted | 77.15% | 65.31% | 60.85% | 59.22% | 66.58% |
| Normalized Diluted EPS | 77.64% | 65.45% | 60.89% | 59.23% | 62.70% |
| Average Basic Shares Outstanding | 1,532.59% | 765.04% | 76.26% | 43.98% | 66.21% |
| Average Diluted Shares Outstanding | 1,532.59% | 765.04% | 76.26% | 43.98% | 66.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -0.32% | -0.80% | -0.78% | -0.64% | -0.55% |
